These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 16473346)

  • 21. Human H9 cells proliferation is differently controlled by vasoactive intestinal peptide or peptide histidine methionine: implication of a GTP-insensitive form of VPAC1 receptor.
    Goursaud S; Pineau N; Becq-Giraudon L; Gressens P; Muller JM; Janet T
    J Neuroimmunol; 2005 Jan; 158(1-2):94-105. PubMed ID: 15589042
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of vasoactive intestinal peptide in inflammation and autoimmunity.
    Gonzalez-Rey E; Delgado M
    Curr Opin Investig Drugs; 2005 Nov; 6(11):1116-23. PubMed ID: 16312132
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PACAP and VIP prevent apoptosis in schwannoma cells.
    Castorina A; Tiralongo A; Giunta S; Carnazza ML; Rasi G; D'Agata V
    Brain Res; 2008 Nov; 1241():29-35. PubMed ID: 18835258
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of PACAP and VIP in astroglial functions.
    Masmoudi-Kouki O; Gandolfo P; Castel H; Leprince J; Fournier A; Dejda A; Vaudry H; Tonon MC
    Peptides; 2007 Sep; 28(9):1753-60. PubMed ID: 17655978
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Are vasoactive neuropeptide autoimmune fatigue-related disorders mediated via G protein-coupled receptors?
    Staines D
    Med Hypotheses; 2005; 65(1):29-31. PubMed ID: 15893112
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Location and function of VPAC1, VPAC2 and NPR-C receptors in VIP-induced vasodilation of porcine basilar arteries.
    Grant S; Lutz EM; McPhaden AR; Wadsworth RM
    J Cereb Blood Flow Metab; 2006 Jan; 26(1):58-67. PubMed ID: 15959462
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The respiratory effects of neuropeptides.
    Joos G; Kips J; Pauwels R; Van der Straeten M
    Eur J Respir Dis Suppl; 1986; 144():107-36. PubMed ID: 2427352
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of the vasoactive intestinal polypeptide agonist Ro 25-1553 on induced tone in isolated human airways and pulmonary artery.
    Schmidt DT; Rühlmann E; Waldeck B; Branscheid D; Luts A; Sundler F; Rabe KF
    Naunyn Schmiedebergs Arch Pharmacol; 2001 Oct; 364(4):314-20. PubMed ID: 11683518
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Coronary vascular effects of vasoactive intestinal peptide in the isolated perfused rat heart.
    Sawmiller DR; Henning RJ; Cuevas J; Dehaven WI; Vesely DL
    Neuropeptides; 2004 Oct; 38(5):289-97. PubMed ID: 15464194
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The neuropeptide vasoactive intestinal peptide: direct effects on immune cells and involvement in inflammatory and autoimmune diseases.
    Ganea D; Hooper KM; Kong W
    Acta Physiol (Oxf); 2015 Feb; 213(2):442-52. PubMed ID: 25422088
    [TBL] [Abstract][Full Text] [Related]  

  • 31. VIP-PACAP system in immunity: new insights for multitarget therapy.
    Gomariz RP; Juarranz Y; Abad C; Arranz A; Leceta J; Martinez C
    Ann N Y Acad Sci; 2006 Jul; 1070():51-74. PubMed ID: 16888149
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanisms of vasoactive intestinal peptide-elicited coronary vasodilation in the isolated perfused rat heart.
    Sawmiller DR; Ashtari M; Urueta H; Leschinsky M; Henning RJ
    Neuropeptides; 2006 Oct; 40(5):349-55. PubMed ID: 17030371
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of VIP and PACAP in islet function.
    Winzell MS; Ahrén B
    Peptides; 2007 Sep; 28(9):1805-13. PubMed ID: 17559974
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PACAP, VIP and their receptors in the metazoa: insights about the origin and evolution of the ligand-receptor pair.
    Cardoso JC; Vieira FA; Gomes AS; Power DM
    Peptides; 2007 Sep; 28(9):1902-19. PubMed ID: 17826180
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Basic aspects of vasorelaxant and bronchodilating peptides in clinical use: urodilatin (INN: Ularitide), VIP, and PACAP.
    Meyer M; Flüge T; Kruhøffer M; Forssmann WG
    Ann N Y Acad Sci; 1996 Dec; 805():443-61; discussion 461-3. PubMed ID: 8993423
    [No Abstract]   [Full Text] [Related]  

  • 36. cAMP activation by PACAP/VIP stimulates IL-6 release and inhibits osteoblastic differentiation through VPAC2 receptor in osteoblastic MC3T3 cells.
    Nagata A; Tanaka T; Minezawa A; Poyurovsky M; Mayama T; Suzuki S; Hashimoto N; Yoshida T; Suyama K; Miyata A; Hosokawa H; Nakayama T; Tatsuno I
    J Cell Physiol; 2009 Oct; 221(1):75-83. PubMed ID: 19496170
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of simplified vasoactive intestinal peptide analogs with receptor selectivity and stability for human vasoactive intestinal peptide/pituitary adenylate cyclase-activating polypeptide receptors.
    Igarashi H; Ito T; Mantey SA; Pradhan TK; Hou W; Coy DH; Jensen RT
    J Pharmacol Exp Ther; 2005 Oct; 315(1):370-81. PubMed ID: 15994369
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PACAP and VIP promote initiation of electrophysiological activity in differentiating embryonic stem cells.
    Chafai M; Louiset E; Basille M; Cazillis M; Vaudry D; Rostène W; Gressens P; Vaudry H; Gonzalez BJ
    Ann N Y Acad Sci; 2006 Jul; 1070():185-9. PubMed ID: 16888163
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The secretin G-protein-coupled receptor family: teleost receptors.
    Cardoso JC; Clark MS; Viera FA; Bridge PD; Gilles A; Power DM
    J Mol Endocrinol; 2005 Jun; 34(3):753-65. PubMed ID: 15956345
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PAC1 receptor: emerging target for septic shock therapy.
    Martínez C; Arranz A; Juarranz Y; Abad C; García-Gómez M; Rosignoli F; Leceta J; Gomariz RP
    Ann N Y Acad Sci; 2006 Jul; 1070():405-10. PubMed ID: 16888200
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.